[Not Available].

Recenti Prog Med

Direttore di Netaudit.

Published: November 2024

Netaudit is a unique, voluntary network of general practitioners in Italy dedicated to conducting audits and research on their clinical practice. Unlike traditional academic research, Netaudit is driven by the grassroots efforts of primary care physicians. The project aims to provide practical tools and support for GPs seeking to improve their clinical practice through data-driven insights. Since its start in 2001, Netaudit has fostered a collaborative community of 150 Italian GPs who share a common interest in Audit and Evidence-based medicine. Members conduct a variety of audits, from monitoring laboratory results to evaluating medication use. Research findings are disseminated through the group's website and a dedicated journal. The project has faced challenges related to data standardization due to the diversity of electronic health record systems used by participating GPs. Despite these challenges, Netaudit has successfully conducted numerous audits over the past two decades, contributing to the evidence base for primary care in Italy. Netaudit has demonstrated the value of peer-led research in improving the quality of care. By empowering GPs to conduct their own research, the project has fostered a culture of continuous learning and quality improvement. Moreover, Netaudit has played a pivotal role in advocating for the academic recognition of general practice in Italy.

Download full-text PDF

Source
http://dx.doi.org/10.1701/4365.43598DOI Listing

Publication Analysis

Top Keywords

clinical practice
8
primary care
8
netaudit
6
[not available]
4
available] netaudit
4
netaudit unique
4
unique voluntary
4
voluntary network
4
network general
4
general practitioners
4

Similar Publications

Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression.

Gastric Cancer

January 2025

Department of Medical Oncology, Hospital Clinico Universitario, INCLIVA, Biomedical Research Institute, University of Valencia, Avenida Menendez Pelayo nro 4 accesorio, Valencia, Spain.

Introduction: Gastric cancer (GC) burden is currently evolving with regional differences associated with complex behavioural, environmental, and genetic risk factors. The LEGACy study is a Horizon 2020-funded multi-institutional research project conducted prospectively to provide comprehensive data on the tumour biological characteristics of gastroesophageal cancer from European and LATAM countries.

Material And Methods: Treatment-naïve advanced gastroesophageal adenocarcinoma patients were prospectively recruited in seven European and LATAM countries.

View Article and Find Full Text PDF

Alcohol-related cirrhosis (AC) is a condition that impacts in immunity. We analyzed changes over time in CD4subsets in AC-patients. We included patients with alcohol use disorder admitted at least twice for treatment.

View Article and Find Full Text PDF

The Stockholm Early Detection of Cancer Study (STEADY-CAN) cohort was established to investigate strategies for early cancer detection in a population-based context within Stockholm County, the capital region of Sweden. Utilising real-world data to explore cancer-related healthcare patterns and outcomes, the cohort links extensive clinical and laboratory data from both inpatient and outpatient care in the region. The dataset includes demographic information, detailed diagnostic codes, laboratory results, prescribed medications, and healthcare utilisation data.

View Article and Find Full Text PDF

Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.

Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.

View Article and Find Full Text PDF

Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults.

Neurol Ther

January 2025

Clinical Pharmacology, AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL, 60064, USA.

Introduction: Atogepant is a calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine in adults in the USA, EU, and several other countries. The objectives of this study were to evaluate the pharmacokinetics (PK) and dose proportionality of atogepant in healthy Japanese participants, evaluate the safety and tolerability of atogepant in Japanese participants, and explore the differences in the PK and safety of atogepant in Japanese vs white participants.

Methods: A total of 50 participants (40 Japanese and 10 white) were enrolled into five cohorts; Japanese cohorts were randomized in a 4:1 ratio to atogepant (10 mg, 30 mg, or 60 mg daily dosing and 60 mg twice daily) or placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!